AU2019219070B2 - Contraceptive composition with reduced cardiovascular effects - Google Patents

Contraceptive composition with reduced cardiovascular effects Download PDF

Info

Publication number
AU2019219070B2
AU2019219070B2 AU2019219070A AU2019219070A AU2019219070B2 AU 2019219070 B2 AU2019219070 B2 AU 2019219070B2 AU 2019219070 A AU2019219070 A AU 2019219070A AU 2019219070 A AU2019219070 A AU 2019219070A AU 2019219070 B2 AU2019219070 B2 AU 2019219070B2
Authority
AU
Australia
Prior art keywords
risk
estetrol
component
vte
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019219070A
Other languages
English (en)
Other versions
AU2019219070A1 (en
Inventor
Maud JOST
Glwadys RAUSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Publication of AU2019219070A1 publication Critical patent/AU2019219070A1/en
Assigned to ESTETRA SRL reassignment ESTETRA SRL Amend patent request/document other than specification (104) Assignors: ESTETRA SPRL
Application granted granted Critical
Publication of AU2019219070B2 publication Critical patent/AU2019219070B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2019219070A 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects Active AU2019219070B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18155571.5 2018-02-07
EP18160586 2018-03-07
EP18160586.6 2018-03-07
PCT/EP2019/052980 WO2019154899A1 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Publications (2)

Publication Number Publication Date
AU2019219070A1 AU2019219070A1 (en) 2020-09-24
AU2019219070B2 true AU2019219070B2 (en) 2024-12-19

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019219070A Active AU2019219070B2 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN115429806A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018024912A1 (en) * 2016-08-05 2018-02-08 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CA2762640A1 (en) * 2009-05-22 2010-11-25 Stefanie Lindemann Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP6447931B2 (ja) * 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． エステトロール成分を含有する口腔内崩壊固体単位剤形
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018024912A1 (en) * 2016-08-05 2018-02-08 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APTER, D. et al. "Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA) Contraception (2016) vol. 94, pages 366-373 *
DAN APTER: "Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control", THE EUROPEAN JOURNAL OF CONTRACEPTION & REPRODUCTIVE HEALTH CARE *
KLUFT et al. "Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol", CONTRACEPTION, vol. 95, 2017, pages 140-147 *

Also Published As

Publication number Publication date
JP2024009834A (ja) 2024-01-23
CN111683664A (zh) 2020-09-18
JOP20200169A1 (ar) 2020-07-07
IL276584B2 (en) 2024-10-01
CA3178181A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
EP3749327A1 (en) 2020-12-16
TW202011967A (zh) 2020-04-01
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
IL276584A (en) 2020-09-30
JP7651645B2 (ja) 2025-03-26
NZ766027A (en) 2026-03-27
GEP20227407B (en) 2022-08-25
PH12020500601A1 (en) 2021-05-17
CN115429806A (zh) 2022-12-06
WO2019154899A1 (en) 2019-08-15
KR20200118464A (ko) 2020-10-15
CA3089804A1 (en) 2019-08-15
UY38075A (es) 2019-10-01
MA51733A (fr) 2020-12-16
CL2020002017A1 (es) 2020-12-04
EP4140489A1 (en) 2023-03-01
PY1908892A (es) 2019-10-15
TWI845496B (zh) 2024-06-21
JP2021513507A (ja) 2021-05-27
UA126746C2 (uk) 2023-01-18
KR102717921B1 (ko) 2024-10-16

Similar Documents

Publication Publication Date Title
AU2019219070B2 (en) Contraceptive composition with reduced cardiovascular effects
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
Klipping et al. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
JP6557298B2 (ja) 副作用（ｖｔｅリスク、頭痛）を軽減し、月経困難症および月経痛の症状を軽減する方法
Hee et al. Continuous use of oral contraceptives: an overview of effects and side‐effects
Stanczyk et al. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations
Klipping et al. Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
Castelli Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke
KR20190076014A (ko) 월경통 및 생리통의 관리방법
Zahradnik et al. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)—an open-label, prospective, noncontrolled, office-based Phase III study
Foidart et al. The benefits of estetrol addition to drospirenone for contraception
Keam et al. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive
EP1558265A1 (en) Cardiovascular protection using anti-aldosteronic progestins
HK40081220A (en) Contraceptive composition with reduced cardiovascular effects
US7786101B2 (en) Cardiovascular protection using anti-aldosteronic progestins
EA048171B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
EA048537B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
RUKHLIADA et al. Visanne and Qlaira in therapy of metrorrhagic adenomyosis, leading to excessive menstrual blood loss and anemia
Pallavee et al. Peripheral arterial disease in a female using high-dose combined oral contraceptive pills
Küçük et al. The effect of low-dose combined oral contraceptive containing 100 ug levonorgestrel on plasma plasminogen activator inhibitor-1 concentrations
Venous Does the Progestogen Used
Shoupe et al. History Pharmacology Metabolic Effects, Side Effects and Health Benefits
Palshetkar et al. Tackling PCOS with Hormonal Contraceptives

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ESTETRA SRL

Free format text: FORMER NAME(S): ESTETRA SPRL

FGA Letters patent sealed or granted (standard patent)